Medifast MED Cash, Cash Equivalents, And Short-Term Investments, Fair Value Disclosure
Other financials
Where this comes from
Reported directly by Medifast in its filing.
Tagged under the XBRL concept med:CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure.
The official record: Medifast’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Medifast's cash, cash equivalents, and short-term investments, fair value disclosure.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Medifast's cash, cash equivalents, and short-term investments, fair value disclosure?
- Medifast (MED) reported cash, cash equivalents, and short-term investments, fair value disclosure of $168.95M in Q1 2026.
- How has Medifast's cash, cash equivalents, and short-term investments, fair value disclosure changed year-over-year?
- Medifast's cash, cash equivalents, and short-term investments, fair value disclosure increased by 2.6% year-over-year, from $164.59M to $168.95M.
- What is the long-term trend for Medifast's cash, cash equivalents, and short-term investments, fair value disclosure?
- Over 3 years (2022 to 2025), Medifast's cash, cash equivalents, and short-term investments, fair value disclosure has grown at a 24.0% compound annual growth rate (CAGR), from $87.69M to $167.27M.